Antituberculosis in pregnancy: a review
DOI:
https://doi.org/10.33448/rsd-v9i6.3714Keywords:
Anti-tuberculosis drugs; Tuberculosis; Mycobacterium tuberculosis.Abstract
Tuberculosis is a contagious disease that primarily affects the lungs, being triggered by Mycobacterium tuberculosis, presenting difficult treatment especially during pregnancy due to the existence of risks to the pregnant woman and the fetus. This study aimed to conduct a literature review related to the use of antituberculosis drugs in pregnancy, highlighting the possible risks. The search for articles occurred in the Lilacs, PubMed, Science Direct and Periodical CAPES databases, including only those published between the years 2005 to 2019. In Brazil, treatment is done primarily through rifampicin, isoniazid, pyrazinamide and ethambutol , and as second-line drugs are aminoglycosides, quinolones and fluorquinolones. Rifampicin has a congenital anomaly rate two to three times higher when compared to isoniazid and ethambutol; isoniazid is recommended as chemoprophylaxis in pregnant women with positive sputum smear microscopy and/or diagnosed with hematogenous disseminated tuberculosis; ethambutol has not been associated with any type of malformation, whereas pyrazinamide is not recommended during pregnancy. Aminoglycosides, quinolones and their derivatives, are associated with malformations and embryotoxicity, and their use is discouraged. Thus, due to the literary scarcity related to the risks associated with the use of antituberculosis drugs during pregnancy, it is necessary to develop cohort studies that bring information about these drugs in the different trimesters of pregnancy.
References
Abdel-Aal, M.A.A., Abdel-Aziz, S.A., Shaykoon, M.A.S. & Abuo-Rahma, G.E.D.A. (2019). Towards anticâncer fluorquinolones: a review article. Archiv der Pharmazie, 352(7): 1-19.
Acar, S., Keskin-Arslan, E., Erol-Coskun, H., Kaya-Temiz, T. & Kaplan, Y. C. (2019). Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis. Reproductive Toxicology, 85: 65 - 74.
Annamruji, H. & Mackillop, L. (2017). Respiratory disease in pregnancy. Obstetrics, Gynaecologya & Reproductive Medicine, 27(4): 105-111.
Anvisa. (2010). Resolução da diretoria colegiada - Consulta Pública nº 116, de 23 de dezembro de 2010. Acesso em 05 julho de 2019, em http://portal.anvisa.gov.br/documents/33836/350888/116.pdf/b9adb5e9-362b-4e65-832e-1338bfe12e92?version=1.0
Arbex, M. A.; Varella, M. C. L.; Siqueira, H. R. & Mello, F. A. F. (2010a). Drogas antituberculose: interações medicamentosas, efeitos adversos utilização em situações especiais. Parte 1: fármacos de primeira linha. Jornal Brasileiro de Pneumologia, 36(5): 626 - 640.
Arbex, M. A.; Varella, M. C. L.; Siqueira, H. R. & Mello, F. A. F. (2010b). Drogas antituberculose: interações medicamentosas, efeitos adversos utilização em situações especiais. Parte 2: fármacos de segunda linha. Jornal Brasileiro de Pneumologia, 36(5): 641 - 656.
Baddour, L. M.; Dayer, M. & Thornhill, M. H. (2018). Fluoroquinolone use and associated adverse drug events in England. Journal of Infection, 78(3): 249-259.
Barbalho, A. M. D. S.; Andrade Júnior, F. P.; Souza, E. K. M.; Lima, I. O.; Farias, A. D.; Souza, J. B. P. (2019). Journal of Medicine and Health Promotion, 4(4): 1267-1279.
Bates, M.; Ahmed, Y.; Kapata, N.; Maeurer, M.; Mwaba, P. & Zumla, A. (2015). Perspectives on tuberculosis in pregnancy. International Journal of Infectious Diseases, 32: 124-127.
Bookstaver, P. B.; Bland, C. M.; Griffin, B.; Stover, K. R.; Eiland, L. S. & McLaughlin, M. A review of antibiotic use in pregnancy. Pharmactherapy, 35(11): 1052-1062.
Branco, B. P. C.; Raso, T. C. M.; Araújo, F. V. & Matos, D. T. (2009). Tuberculose e gravidez: mitos e verdades. Revista Brasileira de Ciências da Saúde, 13(3): 55-60.
Brasil. (2019). Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Manual de recomendações para o controle da tuberculose no Brasil. 2.ed. Brasília (DF): Ministério da Saúde.
Brigden, G.; Hewison, C. & Varaine, F. (2015). New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infection and Drug Resistance. 8: 367-378.
Brito, J. G. E.; Alencar, C. C. A.; Santos, J. P. N.; Ribeiro, A. S. & Lima, S. V. M. A. (2019). Perfil epidemiológico e fator associado à tuberculose. In: Congresso Nacional de Enfermagem-CONENF.
Cadena, A. M.; Fortune, S. M. & Flynn, J. L. Heterogeneity in tuberculosis. Nature Reviews Immunology, 17(11): 691-702.
Caldas, A. (2018). Tuberculose: uma revisão acerca do diagnóstico e tratamento. Revista UNIPLAC, 6(1).
El Shamy, T. & Tamizian, O. (2018). Principales of prescribing in pregnancy. Obstetrics, Gynaecology & Reproductive Medicine, 28(5): 136-140.
Esposito, S.; Bianchini, S. & Blasi, F. (2015). Bedaquiline and delamanid in tuberculosis. Expert Opinion on Pharmacotherapy, 16(15): 2319-2330.
Fan, Y. L.; Wu, J.B.; Cheng, X.W.; Zhang, F. Z. & Feng, L.S. (2018). Fluoroquinolone derivatives and their anti-tubercular activities. European Journal of Medicinal Chemistry, 146: 554–563.
Ferreira, J.; Hermes, A. & Alves, L. M. S. (2016). Atenção primária em saúde: a atuação da enfermagem no controle da tuberculose. Anais do Salão de Ensino e de Extensão.
Garbis, H.; Van Tonningen, M. R. & Reuvers, M. (2007). Anti-infectious agents. Drugs During Pregnancy and Lactation,123–177.
Gould, J. M. & Aronoff, S. C. (2017). Tuberculosis and Pregnancy—Maternal, Fetal, and Neonatal Considerations. In: Bacterial Pathogenesis; Clinical Microbiology, Chapter 33.
Grange, J.; Adhikari, M.; Ahmed, Y.; Mwaba, P.; Dheda, K.; Hoelscher, M.; Zumla, A. (2010). Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. Int J Gynaecol Obstet, 3:181-183.
Guimarães, D. O.; Momesso, L. S. & Pupo, M. T. (2010). Antibióticos: importância terapêutica e perspectivas para a descoberta e desenvolvimento de novos agentes. Química Nova, 33(3): 667-679.
Jabeen, K.; Shakoor, S. & Hasan, R. (2015). Tuberculose resistente à fluoroquinolona: implicações em contextos com sistemas de saúde fracos. Jornal Internacional de Doenças Infecciosas, 32: 118-123
.
Jackson, M. A. & Schutze, G. E. (2019). The use of systemic and topical fluoroquinolones. Pediatrics, 138(5): 1-15.
Katzung, G. B. & Trevor, A. J. (2017). Farmacologia básica e clínica. 13ª ed. Porto Alegre: AMGH.
Leeper, C. & Lutzkanin, A. (2018). Infections during pregnancy. Prim Care. 45(3): 567-586.
Leggett, J. E. (2017). Aminoglycosides. Infectious Diseases. 4ª ed.
Lima, C. H. S.; Bispo, M. L. F. & Souza, M. V. N. Pirazinamida: Um fármaco essencial no tratamento da tuberculose. Revista Virtual de Química, 3(3): 159-180.
Lima, M. R. G.; Coelho, A. S. F.; Salge, A. K. M.; Guimarães, J. V.; Costa, P. S.; Sousa, T. C. C.; Mattos, D. V. & Sousa, M. A. S. Alterações maternas e desfecho gravídico-puerperal na ocorrência de óbito materno. Cadernos Saúde Coletiva, 25(3): 324-331.
Logan. S. & Price, L. (2011). Infectious disease in pregnancy. Obstetrics, Gynaecology & Reproductive Medicina, 1(12): 331-338.
Mehta, N.; Chen, K.; Hardy, E. & Powrie, R. (2015). Respiratory disease in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology, 29(5): 598-611.
Melo, V.V.; Duarte, I.P. & Soares, A. Q. (2012). Guia antimicrobianos. Goiânia: UFG.
Migliori, G. B. & Zumla, A. (2017). Antituberculosis agents. Infectious Diseases.
Oliveira, J. F.; Cipullo, J. P. & Burdmann, E. A. (2006). Nefrotoxicidade dos aminoglicosídeos. Brazilian Journal of Cardiovascular Surgery, 31(4): 444–452.
Organização Mundial de Saúde. Relatório Mundial de Tuberculose. (2018). Geneva: OMS.
Pereira, A.S. et al. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB/NTE/UFSM. Disponível em: https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1. Acesso em: 16 Abril 2020.
Pranger, A. D.; Werf, T. S. Van Der; Kosterink, J. G. W. & Alffenaar, J. W. C. (2019). The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. Drugs. 79(2): 161-171.
Souza, M. V. N. (2005). Rifampicina, um importante fármaco no combate a tuberculose. Revista Brasileira de Farmácia. 86(3): 92-94.
Souza, M. V. N. & Vasconcelos, T. R. A. (2005). Fármacos no combate à tuberculose: passado, presente e futuro. Química Nova, 28(4): 678-682.
Stone, S. & Nelson-Piercy, C. (2010). Respiratory disease in pregnancy. Obstetrics, Gynaecology & Reproductive Medicine, 20(1): 14-21.
Suaifan, G. A. R. Y. & Mohammed, A. A. M. (2019). Fluoroquinolones structural and medicinal developments (2013-2018): where are we now? Bioorganic & Medicinal Chemistry, 27(14): 3005-3060.
Sulis, G. & Pai, M. (2018). Tuberculosis in pregnancy: a treacherous yet neglected Issue. Journal of Obstetrics and Gynaecology Canada, 40(8): 1003-1005.
Titarenko, A. F.; Davies, G. R. & Ziganshina, L. E. (2013). Fluoroquinolones for treating tuberculosis (presumed drugsensitive). Cochrane Database of Systematic Reviews, 6: 1-83.
World Health Organization. (2010). The Treatment of Tuberculosis Guidelines. Geneva: World Health Organization.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.